Across TCGA pan-cancer cohorts, AHNAK2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AHNAK2 data layer compared with 24 for mass-spec protein and 14 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AHNAK2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AHNAK2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where AHNAK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.742	1.000	.001	27	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	5	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.911	.036	4	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AHNAK2 tumor-vs-normal RNA expression · all AHNAK2 data types